West Pharmaceutical Services, Inc.WSTNYSE
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+17.6%
5Y CAGR+53.7%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+17.6%/yr
Quarterly compound
5Y CAGR
+53.7%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
8.6x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 27.49% |
| Q3 2025 | -10.47% |
| Q2 2025 | 17.18% |
| Q1 2025 | -11.89% |
| Q4 2024 | 19.35% |
| Q3 2024 | -11.43% |
| Q2 2024 | -0.57% |
| Q1 2024 | -4.35% |
| Q4 2023 | 12.20% |
| Q3 2023 | -0.61% |
| Q2 2023 | -3.51% |
| Q1 2023 | 7.55% |
| Q4 2022 | 16.91% |
| Q3 2022 | -5.56% |
| Q2 2022 | -1.37% |
| Q1 2022 | 6.57% |
| Q4 2021 | 4.58% |
| Q3 2021 | -5.07% |
| Q2 2021 | 13.11% |
| Q1 2021 | -5.43% |
| Q4 2020 | 3.20% |
| Q3 2020 | 15.74% |
| Q2 2020 | 0.93% |
| Q1 2020 | 4.90% |
| Q4 2019 | 9.68% |
| Q3 2019 | -3.13% |
| Q2 2019 | -2.04% |
| Q1 2019 | 0.00% |
| Q4 2018 | -2.97% |
| Q3 2018 | -6.48% |
| Q2 2018 | 12.50% |
| Q1 2018 | -1.03% |
| Q4 2017 | 6.59% |
| Q3 2017 | -9.00% |
| Q2 2017 | -2.91% |
| Q1 2017 | 7.29% |
| Q4 2016 | 6.67% |
| Q3 2016 | 2.27% |
| Q2 2016 | -6.38% |
| Q1 2016 | -6.00% |